Premium
Avant Immunotherapeutics (MM) (AVAN)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) (the ?Company?), today announced that, pursuant to a previously announced shareholder vote, the Company will change its name to...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
Please replace the release with the following corrected version due to multiple revisions. AVANT REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Conference Call...
AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported financial results for the second quarter and six-month period ended June 30, 2008. AVANT reported a net loss of...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its second quarter 2008 financial results before U.S. financial markets open on August 6, 2008. AVANT executives...
Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) today announced multi-year clinical research collaborations with the 3M to...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious...
PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics)(NASDAQ:AVAN) announced today that its lead product candidate...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
